Clinical Importance of Glucose Regulation in Relapsing MS

NCT ID: NCT03004079

Last Updated: 2018-11-07

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 160 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-10-31
• Study Completion Date: 2020-09-30

Brief Summary

The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery from the relapse.

Steroid exposure commonly leads to elevated serum blood glucose, however, standardized monitoring of blood glucose levels in the outpatient setting is not common. The clinical impact of any associated elevated blood glucose during steroid administration is unknown. We hypothesize that the blood glucose response to steroid treatment is clinically relevant to the MS-relapse recovery.

Detailed Description

Multiple Sclerosis (MS) is a neuroinflammatory and degenerative central nervous system disorder. The majority of patients have an early relapsing-remitting course. Standard treatment for an MS-relapse is intravenous methylprednisolone (IVMP), typically 1000 mg daily for 3 days. Despite IVMP treatment, >40% of MS patients experience residual deficits after an MS-relapse. Potential risk factors for poor relapse recovery remain unclear.

Elevated serum blood glucose is a common and well-defined consequence of steroid administration, attributed to steroid-related reductions in insulin sensitivity. Individuals with pre-treatment insulin resistance (e.g. diabetics) will exhibit an amplified hyperglycemic response. Reduced mobility, sedentary lifestyle, and repeated exposure to steroids- all of which are common in MS - are recognized risk factors for insulin resistance. These factors may make MS patients particularly susceptible to steroid-induced hyperglycemia. While, MS patients commonly receive intravenous steroids, the clinical impact of any associated hyperglycemia is unknown.

Study Design and Methods Timeline: Study will require 3 visits over a 6 month period.

Subjects: MS subjects who are experiencing an acute relapse will be recruited for the study. Prior to any study procedures, the PI or research coordinator will obtain full written informed consent.

Baseline Measurements: age, race/ethnicity, sex, weight, height, waist circumference, blood pressure, previous steroid exposure (dates, frequency, steroid type and dose), smoking history, and family history of diabetes. Medication review will include MS disease-modifying therapy, symptomatic medications, and non-MS-related medications. Additional MS-related information will include dates of initial MS-symptom onset, MS diagnosis, and onset of presenting relapse symptoms.

Oral glucose tolerance test (OGTT) & Matsuda Index: Prior to steroid administration, MS subjects will undergo a 2-hour OGTT. OGTT and Matsuda Index will then be repeated at the 3- and 6-month follow-up visits.

Blood studies: HgA1c (hemoglobin A1C), a fasting lipid panel (LDL-C, HDL-C, triglycerides, and total cholesterol), insulin growth factor, vitamin D level, adiponectin level, homocysteine level, and leptin level. All laboratory tests completed at baseline, 3- and 6-month visits.

Surveys: Subjects will complete surveys related to their perceived disability, relapse severity and recovery, and other MS-related symptoms.

Functional testing: EDSS, MS Functional Composite, timed-walk testing, accelerometry, low contrast visual acuity test (LCVA) and the symbol digit modality test (SDMT).

Intravenous steroid treatment: Standardized 1000 mg of intravenous methylprednisolone (IVMP) daily for 3 days (reconstituted in 0.9% sodium chloride). IVMP will be billed to patient insurance as part of routine clinical care.

Blood glucose monitoring: Bayer Contour Next glucometer will be used to measure capillary BG levels 6 times daily (Subjects will be instructed to check their BG starting on the day of screening and to continue BG checks (as above) until their return appointment 5-7 days after steroid treatment completion for a total of 8-10 days. Subjects will be required to avoid snacks between meals for the 3 days of IVMP treatment.

Conditions

Relapsing Remitting Multiple Sclerosis; Clinically Isolated Syndrome

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Ability to provide informed consent
• Age 18 -59 years (inclusive)
• Ability to walk continuously for 6 minutes (per patient report)
• Clinically Isolated Syndrome (CIS) or Relapsing Remitting MS (RRMS) confirmed diagnosis by McDonald 2010 criteria

• Current MS relapse with objective findings on exam
• Relapse symptom onset within 2-weeks of screening
• Functional System Scores obtainable from a clinic visit within 6 months of the relapse assessment visit
• EDSS < 6.5 at time of screening visit
• Inpatient, outpatient, emergency department, or inpatient observation status

Exclusion Criteria

• Prior steroid exposure within 90 days of enrollment
• HgA1c ≥ 6.5 at baseline screening
• Evidence of concurrent infection
• Known contraindications to IV steroid treatment
• History of diabetes mellitus ( type 1 or 2) or severe hypertension
• Use of any glucose-regulating medications
• Pregnancy or current use of hormone replacement therapy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 59 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Multiple Sclerosis Society

OTHER

Sponsor Role: collaborator

University of Virginia

OTHER

Sponsor Role: lead

Responsible Party

Myla Goldman, MD

Associate Professor of the Department of Neurology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Myla Goldman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Virginia

Locations

University of Virginia

Charlottesville, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Myla Goldman, MD

Role: CONTACT

434-243-6069

Rachael Coleman, MPH

Role: CONTACT

rcoleman@virginia.edu

434-297-4102

Facility Contacts

Rachael Coleman, MPH

Role: primary

rcoleman@virginia.edu

434-297-4102

References

Nickerson M, Marrie RA. The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. BMC Neurol. 2013 Sep 10;13:119. doi: 10.1186/1471-2377-13-119.

Reference Type: BACKGROUND

PMID: 24016260 (View on PubMed)

Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008 Feb;255(2):280-7. doi: 10.1007/s00415-008-0743-8. Epub 2008 Jan 23.

Reference Type: BACKGROUND

PMID: 18204919 (View on PubMed)

Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 Dec 9;61(11):1528-32. doi: 10.1212/01.wnl.0000096175.39831.21.

Reference Type: BACKGROUND

PMID: 14663037 (View on PubMed)

Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci. 2013 Apr;345(4):274-277. doi: 10.1097/MAJ.0b013e31828a6a01.

Reference Type: BACKGROUND

PMID: 23531958 (View on PubMed)

Johnston KC, Hall CE, Kissela BM, Bleck TP, Conaway MR; GRASP Investigators. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke. 2009 Dec;40(12):3804-9. doi: 10.1161/STROKEAHA.109.561498. Epub 2009 Oct 15.

Reference Type: BACKGROUND

PMID: 19834016 (View on PubMed)

Baker L, Juneja R, Bruno A. Management of hyperglycemia in acute ischemic stroke. Curr Treat Options Neurol. 2011 Dec;13(6):616-28. doi: 10.1007/s11940-011-0143-8.

Reference Type: BACKGROUND

PMID: 21861124 (View on PubMed)

Southerland AM, Johnston KC. Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial. Ann N Y Acad Sci. 2012 Sep;1268(1):72-8. doi: 10.1111/j.1749-6632.2012.06731.x.

Reference Type: BACKGROUND

PMID: 22994224 (View on PubMed)

Bruno A, Biller J, Adams HP Jr, Clarke WR, Woolson RF, Williams LS, Hansen MD. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999 Jan 15;52(2):280-4. doi: 10.1212/wnl.52.2.280.

Reference Type: BACKGROUND

PMID: 9932944 (View on PubMed)

Fang Y, Zhang S, Wu B, Liu M. Hyperglycaemia in acute lacunar stroke: a Chinese hospital-based study. Diab Vasc Dis Res. 2013 May;10(3):216-21. doi: 10.1177/1479164112459663. Epub 2012 Oct 18.

Reference Type: BACKGROUND

PMID: 23079541 (View on PubMed)

Matute C, Domercq M, Perez-Samartin A, Ransom BR. Protecting white matter from stroke injury. Stroke. 2013 Apr;44(4):1204-11. doi: 10.1161/STROKEAHA.112.658328. Epub 2012 Dec 4. No abstract available.

Reference Type: BACKGROUND

PMID: 23212168 (View on PubMed)

Wens I, Dalgas U, Deckx N, Cools N, Eijnde BO. Does multiple sclerosis affect glucose tolerance? Mult Scler. 2014 Aug;20(9):1273-6. doi: 10.1177/1352458513515957. Epub 2013 Dec 17.

Reference Type: BACKGROUND

PMID: 24347183 (View on PubMed)

Sternberg Z, Leung C, Sternberg D, Li F, Karmon Y, Chadha K, Levy E. The prevalence of the classical and non-classical cardiovascular risk factors in multiple sclerosis patients. CNS Neurol Disord Drug Targets. 2013 Feb 1;12(1):104-11. doi: 10.2174/1871527311312010016.

Reference Type: BACKGROUND

PMID: 23244431 (View on PubMed)

Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010 Mar 30;74(13):1041-7. doi: 10.1212/WNL.0b013e3181d6b125.

Reference Type: BACKGROUND

PMID: 20350978 (View on PubMed)

Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009 Jan 13;72(2):117-24. doi: 10.1212/01.wnl.0000333252.78173.5f. Epub 2008 Oct 29.

Reference Type: BACKGROUND

PMID: 18971448 (View on PubMed)

Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998 Aug;51(2):529-34. doi: 10.1212/wnl.51.2.529.

Reference Type: BACKGROUND

PMID: 9710030 (View on PubMed)

Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003 Jun;9(3):260-74. doi: 10.1191/1352458503ms914oa.

Reference Type: BACKGROUND

PMID: 12814173 (View on PubMed)

Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec;63(12):1686-91. doi: 10.1001/archneur.63.12.1686.

Reference Type: BACKGROUND

PMID: 17172607 (View on PubMed)

Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012 Mar;125(3):180-6. doi: 10.1111/j.1600-0404.2011.01526.x. Epub 2011 May 26.

Reference Type: BACKGROUND

PMID: 21615355 (View on PubMed)

Godoy DA, Di Napoli M, Rabinstein AA. Treating hyperglycemia in neurocritical patients: benefits and perils. Neurocrit Care. 2010 Dec;13(3):425-38. doi: 10.1007/s12028-010-9404-8.

Reference Type: BACKGROUND

PMID: 20652767 (View on PubMed)

Sala F, Menna G, Bricolo A, Young W. Role of glycemia in acute spinal cord injury. Data from a rat experimental model and clinical experience. Ann N Y Acad Sci. 1999;890:133-54. doi: 10.1111/j.1749-6632.1999.tb07989.x.

Reference Type: BACKGROUND

PMID: 10668421 (View on PubMed)

Zhao QJ, Zhang XG, Wang LX. Mild hypothermia therapy reduces blood glucose and lactate and improves neurologic outcomes in patients with severe traumatic brain injury. J Crit Care. 2011 Jun;26(3):311-5. doi: 10.1016/j.jcrc.2010.08.014. Epub 2010 Oct 2.

Reference Type: BACKGROUND

PMID: 20889287 (View on PubMed)

Selwyn R, Hockenbury N, Jaiswal S, Mathur S, Armstrong RC, Byrnes KR. Mild traumatic brain injury results in depressed cerebral glucose uptake: An (18)FDG PET study. J Neurotrauma. 2013 Dec 1;30(23):1943-53. doi: 10.1089/neu.2013.2928. Epub 2013 Oct 2.

Reference Type: BACKGROUND

PMID: 23829400 (View on PubMed)

Johnston KC, Connors AF Jr, Wagner DP, Knaus WA, Wang X, Haley EC Jr. A predictive risk model for outcomes of ischemic stroke. Stroke. 2000 Feb;31(2):448-55. doi: 10.1161/01.str.31.2.448.

Reference Type: BACKGROUND

PMID: 10657421 (View on PubMed)

Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 6;363(9411):768-74. doi: 10.1016/S0140-6736(04)15692-4.

Reference Type: BACKGROUND

PMID: 15016487 (View on PubMed)

Vespa P, McArthur DL, Stein N, Huang SC, Shao W, Filippou M, Etchepare M, Glenn T, Hovda DA. Tight glycemic control increases metabolic distress in traumatic brain injury: a randomized controlled within-subjects trial. Crit Care Med. 2012 Jun;40(6):1923-9. doi: 10.1097/CCM.0b013e31824e0fcc.

Reference Type: BACKGROUND

PMID: 22610193 (View on PubMed)

Moro N, Ghavim S, Harris NG, Hovda DA, Sutton RL. Glucose administration after traumatic brain injury improves cerebral metabolism and reduces secondary neuronal injury. Brain Res. 2013 Oct 16;1535:124-36. doi: 10.1016/j.brainres.2013.08.044. Epub 2013 Aug 29.

Reference Type: BACKGROUND

PMID: 23994447 (View on PubMed)

Nijland PG, Michailidou I, Witte ME, Mizee MR, van der Pol SM, van Het Hof B, Reijerkerk A, Pellerin L, van der Valk P, de Vries HE, van Horssen J. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions. Glia. 2014 Jul;62(7):1125-41. doi: 10.1002/glia.22667. Epub 2014 Apr 1.

Reference Type: BACKGROUND

PMID: 24692237 (View on PubMed)

Bruno A, Kent TA, Coull BM, Shankar RR, Saha C, Becker KJ, Kissela BM, Williams LS. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke. 2008 Feb;39(2):384-9. doi: 10.1161/STROKEAHA.107.493544. Epub 2007 Dec 20.

Reference Type: BACKGROUND

PMID: 18096840 (View on PubMed)

Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med. 1983 Apr;74(4):540-4. doi: 10.1016/0002-9343(83)91007-0.

Reference Type: BACKGROUND

PMID: 6837584 (View on PubMed)

Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci. 2003 Feb 15;206(2):187-91. doi: 10.1016/s0022-510x(02)00421-5.

Reference Type: BACKGROUND

PMID: 12559509 (View on PubMed)

Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology. 2001 Oct 9;57(7):1239-47. doi: 10.1212/wnl.57.7.1239.

Reference Type: BACKGROUND

PMID: 11591843 (View on PubMed)

Viardot A, Grey ST, Mackay F, Chisholm D. Potential antiinflammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology. 2007 Jan;148(1):346-53. doi: 10.1210/en.2006-0686. Epub 2006 Sep 28.

Reference Type: BACKGROUND

PMID: 17008395 (View on PubMed)

Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):119-25. doi: 10.1007/s00005-012-0210-1. Epub 2013 Jan 10.

Reference Type: BACKGROUND

PMID: 23307037 (View on PubMed)

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. doi: 10.1172/JCI29069.

Reference Type: BACKGROUND

PMID: 16823477 (View on PubMed)

Kallaur AP, Oliveira SR, Colado Simao AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM. Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep. 2013 Mar;7(3):1010-20. doi: 10.3892/mmr.2013.1256. Epub 2013 Jan 2.

Reference Type: BACKGROUND

PMID: 23292766 (View on PubMed)

Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol. 1992 Mar;49(3):265-70. doi: 10.1001/archneur.1992.00530270079022.

Reference Type: BACKGROUND

PMID: 1536629 (View on PubMed)

Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A, Sahraian MA, Motevalian A, Norouzi A, Sanoobar M, Eskandari G, Farhoudi M, Amani F. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21(6):291-6. doi: 10.1159/000356145. Epub 2014 May 6.

Reference Type: BACKGROUND

PMID: 24821457 (View on PubMed)

Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005 May;106(2):163-77. doi: 10.1016/j.pharmthera.2004.11.007. Epub 2005 Jan 11.

Reference Type: BACKGROUND

PMID: 15866318 (View on PubMed)

Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. 2013 Jan 30;5(170):170ra15. doi: 10.1126/scitranslmed.3004970.

Reference Type: BACKGROUND

PMID: 23363979 (View on PubMed)

Warabi Y. Role of IL-1 and potential therapies in multiple sclerosis. Drug Discovery Today: Therapeutic Strategies 2007;4:19-24.

Reference Type: BACKGROUND

Juhler M. Simultaneous determination of regional cerebral blood flow, glucose metabolism, and pH in acute experimental allergic encephalomyelitis. J Cereb Blood Flow Metab. 1987 Oct;7(5):578-84. doi: 10.1038/jcbfm.1987.108.

Reference Type: BACKGROUND

PMID: 3654798 (View on PubMed)

Juhler M. Pathophysiological aspects of acute experimental allergic encephalomyelitis. Acta Neurol Scand Suppl. 1988;119:1-21. doi: 10.1111/j.1600-0404.1988.tb08016.x.

Reference Type: BACKGROUND

PMID: 3064529 (View on PubMed)

JONES HH, JONES HH Jr, BUNCH LD. Biochemical studies in multiple sclerosis. Ann Intern Med. 1950 Oct;33(4):831-40. doi: 10.7326/0003-4819-33-4-831. No abstract available.

Reference Type: BACKGROUND

PMID: 14771754 (View on PubMed)

Sternberg Z, Leung C, Sternberg D, Yu J, Hojnacki D. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis. Cardiovasc Ther. 2014 Apr;32(2):33-9. doi: 10.1111/1755-5922.12049.

Reference Type: BACKGROUND

PMID: 24119301 (View on PubMed)

Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009 Feb 17;72(7):602-8. doi: 10.1212/01.wnl.0000342458.39625.91.

Reference Type: BACKGROUND

PMID: 19221292 (View on PubMed)

Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D, Kollar B. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015 Aug;30(4):895-901. doi: 10.1007/s11011-015-9665-1. Epub 2015 Mar 27.

Reference Type: BACKGROUND

PMID: 25809135 (View on PubMed)

SCHUMACHER GA, BEEBE G, KIBLER RF, KURLAND LT, KURTZKE JF, MCDOWELL F, NAGLER B, SIBLEY WA, TOURTELLOTTE WW, WILLMON TL. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552-68. doi: 10.1111/j.1749-6632.1965.tb20235.x. No abstract available.

Reference Type: BACKGROUND

PMID: 14313512 (View on PubMed)

Other Identifiers

19259

Identifier Type: -

Identifier Source: org_study_id